According to this threshold, 13 patients with cancer exhibited serum binding to MET: 8 patients with breast cancer (10.6%) and 5 patients with lung cancer (20%) (Figure 1A, indicated by red asterisks, and Supplemental Table 1). Here, MET is linked to lung cancer.